The over-the-counter Blink product line features eye and contact lens drops, marking another eye care acquisition for Bausch + Lomb. Last week, the company acquired eye drops and a delivery system from Novartis in a deal worth up to $2.5 billion.
Under the terms of this deal, Bausch + Lomb plans to use cash on hand to acquire the Blink line for $106.5 million.
“There’s a growing need for relieving the symptoms of dry eyes and dry contact lenses, and OTC products are often the first option consumers choose,” said John Ferris, EVP, Consumer, Bausch + Lomb. “The addition of Blink expands our robust portfolio of OTC eye care brands, enabling us to provide more choices for consumers and eye care professionals.”
Blink features a variety of eye drops and contact lens resetting drops. They provide immediate and long-lasting symptom relief.
Products involved in the acquisition include:
- Blink Tears Lubricating Eye Drops;
- Blink Tears Preservative Free Lubricating Eye Drops;
- Blink GelTears Lubricating Eye Drops;
- Blink Triple Care Lubricating Eye Drops;
- Blink Contacts Lubricating Eye Drops; and
- Blink-N-Clean Lens Drops.